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Abstract: Innate neuroinflammatory changes, increased oxidative stress and disorders of glutathione 
metabolism may be involved in the pathophysiology of autism spectrum disorders (ASD). Propionic 
acid (PPA) is a dietary and gut bacterial short chain fatty acid which can produce brain and behavioral 
changes reminiscent of ASD following intraventricular infusion in rats. Adult Long-Evans rats were 
given intraventricular infusions of either PPA (.26M, 4µl animal
-1) or phosphate buffered saline (PBS) 
vehicle, twice daily for 7 days. Immediately following the second daily infusion, the locomotor activity 
of each rat was assessed in an automated open field (Versamax) for 30 min. PPA-treated rats showed 
significant  increases  in  locomotor  activity  compared  to  PBS  vehicle  controls.  Following  the  last 
treatment day, specific brain regions were assessed for neuroinflammatory or oxidative stress markers. 
Immunohistochemical  analyses  revealed  reactive  astrogliosis  (GFAP),  activated  microglia  (CD68, 
Iba1) without apoptotic cell loss (Caspase 3’ and NeuN) in hippocampus and white matter (external 
capsule) of PPA treated rats. Biomarkers of protein and lipid peroxidation, total glutathione (GSH) as 
well as the activity of the antioxidant enzymes superoxide dismutase (SOD), catalase, glutathione 
peroxidase (GPx), glutathione reductase (GR) and glutathione S-transferase (GST) were examined in 
brain homogenates. Some brain regions of PPA treated animals (neocortex, hippocampus, thalamus, 
striatum)  showed  increased  lipid  and  protein  oxidation  accompanied  by  decreased  total  GSH  in 
neocortex. Catalase activity was decreased in most brain regions of PPA treated animals suggestive of 
reduced  antioxidant  enzymatic  activity.  GPx  and  GR  activity  was  relatively  unaffected  by  PPA 
treatment while GST was increased, perhaps indicating involvement of GSH in the removal of PPA or 
related catabolites. Impairments in GSH and catalase levels may render CNS cells more susceptible to 
oxidative stress from a variety of toxic insults. Overall, these findings are consistent with those found 
in ASD patients and further support intraventricular PPA administration as an animal model of ASD.  
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INTRODUCTION 
 
  Autism  spectrum  disorder  (ASD)  comprises  a 
family  of  neurodevelopmental  disorders  characterized 
by language impairment, restricted interests, stereotypic 
motor  behaviors,  hyperactivity,  sensory  disturbances 
and self injury
[1,2]. ASD is also associated with seizure 
disorder
[3].  Imaging  and  neuropathological  studies  of 
ASD  patients  have  noted  increased  brain  size,  white 
matter  abnormalities  as  well  as    increased  neuronal 
density      in        neocortical,        limbic  and  cerebellar 
areas
[4-7].  These  findings  suggest  altered 
neurodevelopmental  processes  in  some  brain  areas  in 
ASD  patients.  A  recent  neuropathological  study  of 
autopsy  material  from  ASD  patients  of  varying  ages 
found evidence of a diffuse innate neuroinflammatory 
response  of  unknown  etiology.  This  response  was 
characterized  by  reactive  astrogliosis,  activated Am. J. Biochem. & Biotech., 4 (2): 146-166, 2008 
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microglia and cytokine abnormalities
[8]. These findings 
suggest that an immune-mediated response may persist 
throughout the life of ASD patients
[9].  
  ASD  has  a  strong  genetic  basis  as  the  disorder 
shows high heritability with a concordance rate of 82% 
amongst  monozygotic  twins  and  close  to  0%  for 
dizygotic  twins
[10,11].  ASD  is  also  co-morbid  with  a 
number of other inherited conditions including fragile 
X  syndrome,  tuberous  sclerosis,  Smith-Lemli  Opitz 
syndrome and Mobius syndrome
[12-15]. A panel of genes 
involved  in  brain  development
[16]  and  serotonin
[17], 
glutamate,  or  GABA  metabolism,  have  also  been 
associated with a sub-set of ASD patients
[18].  
  The  lack  of  complete  concordance  as  well  as 
variance  in  the  severity  of  autism  in  monozygotic 
twins
[19]  suggests  that  environmental  factors  are  also 
likely  important  in  ASD  etiology.  Environmental 
factors  may  account  for  some  observed  geographical 
clustering of cases
[20] and may be involved in the recent 
postulated increase in the incidence of  ASD cases in 
North America (approximately 1 in 166)
[21]. There has 
been  growing  interest  in  a  group  of  environmental 
toxins and infectious agents which could act at critical 
periods of pre- and post-natal development to putatively 
trigger  or  exacerbate  this  disorder  in  genetically 
vulnerable  individuals.  An  increased  risk  of  ASD  is 
associated  with  pre-natal  exposure  to  ethanol
[22], 
valproic acid
[23], terbutaline
[24], some metals and viral 
infections
[25,26].  Many  of  these  effects  have  been 
observed  in  animal  models  using  these  toxic  or 
infectious agents. 
  One  common  mechanism  by  which  diverse 
environmental and/or genetic factors could induce the 
diffuse CNS effects seen in ASD is increased oxidative 
stress
[27].  CNS  effects  may  be  produced by  increased 
production of reactive intermediates, impairments in the 
detoxification of these agents, or a combination of these 
factors
[28,29]. Studies of plasma from ASD patients with 
diverse  genetic  backgrounds  provide  evidence  of 
increased  oxidative  stress  involving  reduced  capacity 
for  methylation  and    sulfuration  as  measured  by 
methionine  transmethylation  and  transulfuration 
pathways  and  lipid  peroxidation.  Additional 
observations  have  included  impaired  xenobiotic 
detoxification  and  clearance  at  a  systemic  level
[29-31]. 
Findings  from  these  studies  may  reflect  some  innate 
neuroinflammatory  processes  in  the  brains  of  ASD 
patients
[8].  
  Of  particular  interest  is  the  evidence  of  an 
impairment in glutathione (GSH) associated pathways 
in the plasma of ASD patients
[27,30]. GSH participates in 
both antioxidant defense and xenobiotic detoxification 
over a wide range of environmental organic compounds 
and  metals
[32].  The  GSH  redox  system  consists  of 
primary  and  secondary  antioxidants,  including 
glutathione  peroxidase  (GPx),  glutathione  reductase 
(GR),       glutathione        S-transferase           (GST), 
g -glutamylcysteine    synthetase  ( g -GCS) and glucose 
6-phosphate dehydrogenase (G6PD). Alterations in the 
activities of these enzymes are suggestive of reduced 
cellular defense and are surrogate markers of increased 
oxidative stress
[33]. Furthermore, genetic alterations in 
glutathione metabolism have been noted in some ASD 
populations suggesting a plausible inherited mechanism 
for environmental sensitivity
[34,35]. 
  Many environmental factors have been proposed to 
contribute  to  ASD  pathogenesis.  There  is  growing 
interest in the role that gastrointestinal factors may play 
in  the  behavioral,  neuropathological  and 
neuroinflammatory  sequelae  observed  in  some  ASD 
cases.  Anecdotal  reports  have  suggested  that  ASD 
symptomology  may  be  induced  or  exacerbated 
following  acute  gastrointestinal  abnormalities
[36], 
routine and antibiotic resistant paediatric infections
[37], 
or  ingestion  of  wheat  or  dairy  containing  foods
[38]. 
Gastroenterological studies have revealed evidence of 
ileal lymphoid nodular hyperplasia
[39] and have isolated 
unique  clostridial  species
[40],  in  some  ASD  patients 
exhibiting  regressive  symptoms  after  apparently 
attaining  normal  postnatal  developmental  milestones. 
The linkage between brain and gastrointestinal function 
is  interesting  in  the  light  of  the  recent  discovery  of 
reduced  display  of  MET  gene  expression,  a  factor 
involved in neocortical and cerebellar growth, immune 
function  and  gastrointestinal  repair
[41]  in  some 
subpopulations  of  ASD.  These  findings  raise  the 
possibility that some gut-derived factor may contribute 
to  the  pathogenesis  and  behavioral  abnormalities  of 
ASD. 
  Our  laboratory  has  investigated  the  role  of 
propionic acid (PPA) which is a metabolic intermediate 
of fatty acid metabolism
[42]. PPA is also an end-product 
of  enteric  bacterial  fermentation,  particularly  from 
those  bacteria  implicated  in  antibiotic  associated 
diarrhea
[43,44]. Moreover, PPA is commonly used as a 
food preservative in wheat and dairy food products
[45]. 
A number of effects have been shown following PPA 
treatment, including catecholamine and proenkephalin 
gene  induction
[46],  cytoskeletal  phosphorylation
[47], 
histone  modulation
[48],  second  messenger 
metabolism
[49],  impaired  mitochondrial  respiratory 
transport  chain  function
[50,51],  modulation  of  gap 
junctions
[52] and immune system activation
[53].  
  There is also evidence of variable PPA metabolism 
in a number of metabolic disorders such as propionic 
and  methylmalonic acidemia
[54], disorders of biotin
[55] Am. J. Biochem. & Biotech., 4 (2): 146-166, 2008 
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and  B12  metabolism
[56],  as  well  as  following 
valproate
[57]  and  ethanol  exposure
[58].  These  disorders 
are  associated  with  developmental  delay,  seizure  and 
episodes of paroxysmal metabolic dysfunction resulting 
in  increased  oxidative  stress  and  are  to  some  degree 
reminiscent of autism
[59,60]. We have hypothesized that 
PPA  may  be  a  candidate  environmental  factor 
putatively  involved  in  the  diverse  behavioral, 
neuropathological  and  gastrointestinal  aspects  of 
ASD
[61].   
  In our initial studies we found that repeated micro-
infusions of PPA into the lateral cerebral ventricles of 
adult rats produced behavioral, electrophysiological and 
neuropathological effects consistent with ASD
[61].  PPA 
treated animals exhibited increased locomotor activity 
and  repetitive  behaviors  such  as  dystonic  limb 
movements,  retropulsion  and  axial  hyperextension. 
Simultaneous  electrophysiological  examination  of 
cortical,  hippocampal  and  striatal  EEG  evidenced 
electrographic changes reminiscent of human complex 
partial  seizure  and  movement  disorder.  These  effects 
were  apparent  within  minutes  of  microinfusion. 
Furthermore, repeated exposures resulted in increased 
behavioral  and  electrographic  effects  suggestive  of  a 
kindling process. Collectively these findings indicated 
that PPA may have permanent effects on brain function. 
Neuropathological  analysis  of  hippocampus  and 
external  capsule  white  matter  tissue  revealed  PPA-
related  increases  in  reactive  astrocytes  and  activated 
microglia  in  the  absence  of  gross  neuronal  loss  and 
apoptotic  effects.  Additional  analyses  of  whole  brain 
homogenates produced evidence of increased oxidative 
stress  and  impaired  glutathione  metabolism  in  PPA 
treated animals. These findings are consistent with the 
neuropathological  changes  found  in  ASD  autopsy 
brains
[8]  as  well  as  biochemical  studies  in  ASD 
patients
[27,31]. 
  The present study extended the examination of the 
effects  of  intraventricular  PPA  infusion  on  behavior, 
neuropathology and oxidative stress levels in the adult 
rodent ASD model. In particular, we characterized PPA 
induced increases in locomotor activity with additional 
automated measures of horizontal and vertical activity. 
We  also  examined  the  neuropathological  responses 
following the twice-daily treatment schedule, utilizing 
additional  indices  of  microglial  activation  and 
neurotoxicity.  Lastly,  we  examined  pro-  and  anti-
oxidative stress pathways in brain regions which have 
been previously implicated in ASD pathophysiology.  
 
MATERIALS AND METHODS 
 
Animals  and  housing  facilities:  A  total  of  30  adult 
male Long-Evans (Charles River Laboratories, Quebec) 
rats were used. Rats weighed approximately 200-225 g 
(approximately  47  to  49  days  old)  at  the  time  of 
delivery from the supplier. Animals were individually 
housed  at  a  controlled  temperature  (21±1°C)  with  ad 
libitum access to food (Prolab rat chow) and tap water. 
All behavioral testing occurred during the light phase of 
a 12:12 hr light:dark cycle (lights on 0700h to 1900h) 
under normal lighting conditions. Rats were naive to all 
experimental  procedures  prior  to  surgery.  All 
procedures were in accordance with guidelines of the 
Canadian  Council  on  Animal  Care  (CCAC)  and 
approved by the University of Western Ontario Animal 
Use Committee. 
 
Surgical  procedures  for  cannula  implantation: 
Surgical  procedures  were  completed  under  aseptic 
conditions. All rats were implanted with a 23 ga guide 
cannula using standard stereotaxic techniques. Prior to 
surgery  each  rat  was  pretreated  with  atropine  methyl 
nitrate  (0.1ml  SC).  Rats  were  anaesthetized  using 
inhaled Isoflurane and 3% oxygen and were placed in a 
stereotaxic apparatus. During surgery body temperature 
was maintained at normothermia using a heating pad. 
The tip of the guide cannula was placed immediately 
below the border of the corpus callosum into the lateral 
ventricle (AP 1.3 mm, ML 1.8 mm)
[62]. The tip of the 
30 ga injection cannula protruded 0.5 mm beyond the 
tip of the guide cannula to allow infusion into the lateral 
ventricle. Each cannula was sealed with an obtruator, 
which  was  removed  prior  to  each 
intracerebroventricular  (ICV)  infusion.  Small  screws 
were placed in the top of the skull and the cannula was 
affixed  to  the  skull  with  dental  acrylic.  Testing 
procedures began approximately 14 days after surgery.  
 
Treatment  groups  and  intracerebroventricular 
infusion procedure: Rats were randomly assigned to 
two groups: PPA (4.0 µl of a 0.26 M solution, n = 12); 
and PBS control (4.0µl of .1 M PBS, n = 12). PPA was 
dissolved in PBS vehicle and buffered to pH 7.5 using 
concentrated  HCl  or  NaOH.  Each  group  received 
intracerebroventricular (ICV) infusions twice daily for 
7 consecutive days. Compounds were infused using a 
30  ga  injection  cannula  attached  to  a  Sage  syringe 
pump  with  sterile  PE10  tubing.  Infusions  took  place 
over a 60 sec period. The infusion cannula was allowed 
to remain in place for an additional 60 sec before being 
removed.  Locomotor  activity  assessments  were  made 
each day (D1 to D7) following the second infusion. 
  On  day  8,  brain  tissue  was  extracted  and 
subsequently  assayed  for  biochemical  markers  of 
oxidative  stress  and  neuropathological  markers  (see 
procedures below). A random subset of 6 rats from each Am. J. Biochem. & Biotech., 4 (2): 146-166, 2008 
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treatment group was used for the neuropathological and 
biochemical analyses. An additional set of 6 rats were 
cannulated and treated with PPA twice daily; however, 
locomotor activity was not assessed. Brain tissue from 
this  second  group  of  PPA  animals  was  used  in  the 
biochemical assays. Unless otherwise specified each of 
the biochemical markers were completed with 6 PBS 
and 12 PPA treated rats.  
 
Locomotor activity assessments: Locomotor activity 
was quantified  with eight VersaMax  Animal  Activity 
Monitors  (Model  NVMA16TT/W,  Accuscan 
Instruments  Inc.,  Columbus,  OH).  Each  monitor 
consisted  of  a  40´40´30.5  cm  Plexiglas  open  field 
covered  by  a  Plexiglas  lid  with  air  holes.  Sets  of 
infrared  beams  for  horizontal  activity  measurement 
surrounded the perimeter of each open field. Each beam 
was located every 2.54 cm for a total of 16 beams on 
each of four sides. Each set of infrared beams, used to 
measure horizontal activity, was located 4.5 cm above 
the  floor  of  the  open-field
[63].  Vertical  activity  was 
measured  by  two  additional  sets  of  beams  that  were 
located 15cm above the floor of each open-field. Light 
levels  at  the  floor  level  of  each  open-field  were 
approximately  900lux.    A  VersaMax  Analyser 
(Accuscan Model VSA-16, Columbus, OH) processed 
and relayed data from each automated open-field to a 
computer  located  in  a  room  adjacent  to  the  testing 
room.   
  We previously reported that rats treated with PPA 
traveled significantly greater distances in the VersaMax 
automated  open  field  compared  to  PBS-treated 
controls
[61] . The locomotor activity analyses reported in 
the present study are from the same group of animals 
previously studied but include additional measures of 
locomotor  activity.  The  multiple  activity  variables
[64] 
analyzed in the present study included the following:  
 
Number  of  movements  (NM):  Total  number  of 
horizontal movements separated by 1s of stop time.  
Movement  time  (MT):  Total  amount  of  time  (s) 
engaged in horizontal movement.  
Vertical movements (VM): Total number of vertical 
movements separated by 1s of stop time.  
Vertical time (VT): Total amount of time (s) spent in a 
vertical position. 
  Rats   were    habituated   to the apparatus for two 
30  min  sessions  prior  to  the  treatment  sessions. 
Locomotor activity was recorded during a third baseline 
session to establish activity levels for the untreated rats. 
Habituation  and  baseline  activity  recordings  were 
completed  at  times  that  corresponded  with  future 
treatment sessions.  
  Rats received ICV infusions for 7 days twice daily 
at  9  A.M.  and  1  P.M.  during  the  light  period. 
Locomotor activity was recorded for 30 min on each 
treatment  day  (D1  to  D7)  immediately  following  the 
second  infusion  at  1300h.  The  half  life  of  PPA  is 
estimated  to  be  between  18  and  57  min  when 
administered    to    rats which supports the use of the 
30 min test time
[65].  
 
Assessments of neuropathology 
Tissue  preparation:  On  day  8  animals  were  deeply 
anaesthetized with sodium pentobarbital (270 mg mL
-1 
IP)  and  transcardially  perfused  with  ice  cold  PBS 
(0.1M)  followed  by  4%  paraformaldehyde  in  PBS. 
Brains  were  removed  and  placed  in  4% 
paraformaldehyde solution and stored at 4°C for 24 h. 
Following the fixation period, brains were placed in an 
18%  sucrose  solution  prior  to  paraffin  embedding. 
Selected  coronal  blocks  from  various  brain  regions 
(frontal cortex/striatum, dorsal hippocampus, midbrain 
and  cerebellum/brainstem),  were  dehydrated  and 
defatted  by  increasing  concentrations  of 
ethanol/xylenes  and  embedded  in  paraffin  wax  for 
permanent storage. 
 
Immunohistochemistry  procedures:  Using  a  Leica 
microtome (model RM2125) serial 4 µm sections were 
obtained through the following regions: 1) right lateral 
ventricle  (cannula  site)  and  2)  ipsilateral  dorsal 
hippocampus,  including  adjacent  white  matter  of  the 
external capsule. These anatomical regions were chosen 
for  preliminary  analyses  based  on:  1)  their  close 
proximity to the intraventricular administration site of 
PPA  or  PBS  vehicle,  2)    the  well-known 
cytoarchitectonics of the  hippocampus  which allowed 
for  reliable  quantification  of  possible  PPA-induced 
neuroplastic  changes,  3)  the  known  role  of  the 
hippocampus in experimental kindling, human seizure 
disorder  and  autism  and  4)  for  analysis  of 
oligodendroglial changes in white matter of the external 
capsule, also implicated in autism.   
  The following antibodies  were used: 1) anti-glial 
fibrillary  acidic  protein  (GFAP)  (1:500,  rabbit 
polyclonal,  DakoCytomation,  Glostrup,  Denmark)  a 
marker  for  reactive  astrogliosis,  found  elevated  in 
human  autism  neuropathology  studies
[66]  and  in 
cerebrospinal fluid from autism patients
[67], 2) anti-rat 
CD68  antigen  (1:  200,  monoclonal,  Serotec,  Oxford, 
UK), 3) anti-IbA1 ( 1:10, 000, rabbit polyclonal, Wako, 
Richmond,  VA)  both  markers  for  activated  microglia 
and  found  elevated  in  human  autism  brain
[66]  and 
epilepsy
[68],  4)  anti-cleaved  caspase  3  (1:  100,  rabbit 
polyclonal, Cell Signaling Technology, Danvers, MA), Am. J. Biochem. & Biotech., 4 (2): 146-166, 2008 
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a  marker  for  apoptotic  cytotoxicity
[69,70]  and;  5)  anti-
NeuN (1:1000, monoclonal, Chemicon USA ), a marker 
for neurons
[71].  
  Tissue  sections  were  mounted  on  glass  slides 
(SurgiPath,  Canada)  and  dried  overnight  at  37°C. 
Sections  were  deparaffinized  and  rehydrated  using 
standard immunohistochemical procedures for antigen 
recovery
[72].  Endogenous  peroxidase  activity  was 
blocked  using  a  3%  hydrogen  peroxide  in  distilled 
water solution for 5min.  For antigen recovery, sections 
were immersed in boiling 0.21% citric acid buffer (pH 
6.0) for 30 min in a 1250W microwave oven. Slides 
were  counterstained  with  Gill  haematoxylin  (EMD 
Biosciences) and rinsed with PBS for 5 min. A 10% 
normal horse serum in PBS solution was applied for 5 
min followed by the primary antibodies for 1hr at room 
temperature. Following the incubation period, sections 
were washed with PBS and secondary antibodies, either 
biotinylated  anti-mouse  IgG  (Vector  Laboratories, 
Burlingame,  CA-BA2000)  or  biotinylated  anti-rabbit 
(Vector  Laboratories,  Burlingame  CA-BA1000) for 
30  min.  Tissues  were  again  washed  with  PBS  and 
stained  using  the  avidin-biotin  complex  (Vectastain 
Elite  ABC,  Vector  Laboratories,  Burlingame,  CA-
PK6100)  for  30  min  at  room  temperature.  Following 
incubation,  slides  were  washed  with  PBS  and  3,  3-
diaminobenzidine  DAB  chromagen  (Sigma-D8001) 
was applied for 5 min. After final rinsing, slides were 
dehydrated, cleared and coverslipped.     
 
Immunohistochemistry  quantification:  Using  a 
standard  light  microscope,  8  non-overlapping  digital 
photomicrographs (area = 160,000 µm
2) spanning the 
pyramidal cell layer of the hippocampus (CA1 to CA2 
and CA3 to hilus of the dentate gyrus) as well as the 
stratum  oriens  to  stratum  radiatum  were  captured  at 
250´magnification. From the same section of tissue, an 
additional 7 digital images (area = 160,000 µm
2) of the 
white matter of the external capsule, dorsally adjacent 
to  the  hippocampus,  were  also  captured  sequentially 
starting at the corpus callosum and ending at the lateral 
ventricle. A total of 15 digital photomicrographs were 
taken   for   each animal in each treatment group (PPA, 
n = 6, PBS, n = 6). Photos were captured under fixed 
microscope illumination settings and exposure times to 
ensure consistent image quality across all pictures.  
  To  quantify  immunoreactivity,  a  standard  set  of 
color  recognition  criteria  were  created  for  each 
antibody  to  ensure  that  only  DAB  labelled 
immunopositive cells were recognized by the software. 
Standard color criteria were created for each individual 
antibody  to  counter  the  effects  of  variance  in  the 
intensity  DAB  labelling.  Data  from  images  were 
summed on a per-region basis to yield totals for both 
the  hippocampus  (i.e.,  8  images  summed)  and  white 
matter (i.e., 7 images summed)
[64].  
  Two analysis methods were used for quantification 
of immunoreactivity. Due the diffuse nature of GFAP, 
IbA1 and NeuN staining, analyses were completed by 
using the ‘area stained’ function within ImagePro Plus 
which sums the immunopositive area within a digital 
image  to  provide  a  total  immunopositive  area  per 
picture  (µm
2).  CD68  and  caspase  3’  staining  was 
restricted  within  the  cell  membranes  hence  these 
antibodies  were  quantified  using  the  ‘cell  count’ 
function which counted immunopositive cells only.   
  Finally, the cytotoxicity of PPA was also examined 
via direct visual cell counts of NeuN stained neuron cell 
bodies  (hippocampal  pyramidal  cells)  to  determine 
potential  cell  losses  in  the  hippocampus  only.  Cell 
bodies were counted by a trained scorer who was blind 
to the treatment. Cell bodies were counted only if they 
displayed  an  intact  cell  membrane  and  possessed  a 
visible nucleus.  
 
Assessment of oxidative stress: Biomarkers for lipid 
and  protein  oxidation,  glutathione  (GSH)  and  the 
activity of enzymes involved in glutathione metabolism 
(glutathione  peroxidase  (GPx),  glutathione  reductase 
(GR) and glutathione S-transferase (GST)) were studied 
in whole brain homogenates. Assays were conducted at 
room temperature unless otherwise indicated.  
 
Tissue preparation: At approximately 9 A.M. on day 
8,  rats  were  decapitated  without  anaesthesia.  Brain 
tissue was rapidly excised and dissected, washed with 
ice  cold  PBS,  weighed  and  kept  on  ice  until 
homogenized. The following brain areas were grossly 
dissected  on  ice:    1)  neocortex  ipsilateral  to  drug 
infusion cannula, encompassing all tissue lateral to the 
external capsule; 2) bilateral hippocampal formations; 
2)  basal  ganglia,  encompassing  caudate,  putamen, 
nucleus accumbens and septum; 3) thalamus to caudal 
division between superior and inferior colliculi; 4) brain 
stem, encompassing inferior colliculi to medulla and 5) 
cerebellum,   dissected    from  cerebellar peduncles 
(Fig. 1). Each brain was homogenized in 10 volumes of 
PBS (1:10, w/v; pH 7.4) and centrifuged at 800×g for 
10  min  at  4
°C  to  discard  nuclei  and  cell  debris.  The 
supernatant  was  separated  and  stored  at  -80
°C  until 
needed  for  biochemical  analyses  and  the  pellet  was 
discarded. Am. J. Biochem. & Biotech., 4 (2): 146-166, 2008 
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Fig. 1:  Schematic  representation  of  gross  anatomical 
brain  areas  of  rat  brain  homogenized  for 
analysis  of  biochemical  oxidative  stress 
markers 
 
Oxidative  stress  marker  assays:  Lipid  peroxidation 
was  determined  by  measuring  the  amounts  of  the 
secondary products of malondialdehyde (MDA) and 4-
hydroxyalkenals (HAE), using a commercial kit (LPO-
586;  Calbiochem,  La  Jolla,  CA),  according  to  the 
manufacturer’s  instructions.  Protein  carbonyl 
concentration  was  determined  using  the  Protein 
Carbonyl Assay kit from Cayman Chemical ®, based 
on  the  reaction  between  protein  carbonyls  and  2,4-
dinitrophenylhydrazine  (DNPH)  to  form  the 
corresponding hydrazone
[73].  
  Superoxide dismutase (SOD) activity was assessed 
in the brain homogenates by measuring the dismutation 
of  superoxide  radicals  generated  by  xanthine  oxidase 
and hypoxanthine in a 96 well format using the Cayman 
Chemical® SOD Assay kit (Cayman Chemical Cat. No. 
706002). Catalase activity was measured by using the 
Cayman Chemical® Catalase Assay kit (Cayman Cat. 
No.  707002)  which  is  based  on  the  reaction  of  the 
enzyme  with  methanol in the presence of an optimal 
concentration of H2O2.  
 
Glutathione  (GSH)  system  assays:  Glutathione 
system  assays  were  done  using  available  commercial 
kits  from  Cayman  Chemical®.  All  absorbance 
measurements  were  performed  in  a  Multiskan  ® 
Spectrum  microplate  spectrophotometer  from  Thermo 
Labsystems. 
  Glutathione peroxidase (GPx) activity was assayed 
based  on  the  procedure  described  by  Paglia  et  al.
[74] 
using cumene hydroperoxide as substrate. Glutathione 
reductase  (GR)  activity  was  determined  according  to 
Carlberg and Mannervik
[75].  
  Glutathione  S-transferase  (GST)  was  assessed  by 
the  method  of  Habig  et  al.
[76]  which  measures  the 
conjugation  of  1-chloro-2,4-dinitrobenzene  (CDNB) 
with reduced GSH.  
  Total  GSH  concentrations  were  detected  by  the 
GSH  disulphide  reductase  5,5´-dithiobis  (2-
nitrobenzoic  acid)  recycling  method  using  the 
procedure described in the GSH assay kit from Cayman 
Chemicals ®.  
 
Statistical  Analyses:  Locomotor  activity  data  were 
analyzed  using  a  mixed  design  analysis  of  variance 
(ANOVA) to assess  group differences (i.e., PPA and 
PBS) in activity levels during the baseline (BL) session 
as well as across each of the 7 test days (i.e., D1 to D7). 
Means  of  the  PPA  and  PBS  treated  animals  were 
compared  by  t-tests  for  the  neuropathological  and 
biochemical  data.  Hypothesis  tests  were  completed 
using  a = 0.05 as the criterion for significant effects. 
All statistical tests were calculated using SPSS 13.0 for 
Windows. 
 
RESULTS AND DISCUSSION 
 
Baseline  locomotor  activity:  Analyses  of  baseline 
activity levels of untreated rats revealed no significant 
differences between animals assigned to the PPA and 
PBS groups. This finding suggests that these samples of 
rats  showed  no  inherent  differences  in  locomotor 
activity  prior  to  ICV  infusions  and  that  locomotor 
activity differences exhibited over treatment days were 
attributable to PPA treatment. 
 
Effects of PPA treatment on locomotor activity: The 
analyses  revealed  a  significant  day´treatment 
interaction only for MT (F (7, 154) = 3.02, p = 0.019) 
suggesting  that  the  activity  levels  differed  between 
treatment  groups  across  the  treatment  days.  A 
significant main effect of treatment was also obtained 
for NM and MT (p<0.001, for each) and VM (p <0.01)   
 
Horizontal  activity  variables:  PPA-treated  rats 
showed increased locomotor activity that peaked on D3. 
Simple effects tests were performed for each variable 
across  baseline  and  treatment  days.  PPA-treated  rats 
exhibited a significantly greater number of movements 
(NM)  compared  to  the  PBS  controls  on  each  of 
treatment days 1-6 (p <0.05 or better). PPA-treated rats 
also spent more time moving compared to PBS controls 
on treatment days 1-6 (p <0.05) (Fig. 2).   
 
Vertical  activity  variables:  Analyses  revealed  a 
significant main effect for treatment on vertical activity 
measures.  PPA-treated  rats  produced  more  vertical 
movements  (VM)  and  spent  more  time  in  a  vertical 
position  (VT)  compared  to  PBS-treated  animals  on 
treatment day 6 (p< 0.05 or better) (Fig. 2.)  Am. J. Biochem. & Biotech., 4 (2): 146-166, 2008 
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Fig. 2:  Group mean values (±SEM) number of movements, movement time, vertical movements and vertical time in 
rats given 4µl ICV infusions of PBS or PPA twice daily for 7 days. PBS: phosphate buffered saline, PPA: 
propionic  acid, BL: baseline session with no infusion, D1-D7: 7 consecutive treatment days.  *p< 0.05, 
**p< 0.01 
 
Neuropathology 
GFAP:  Brain  tissue  from  PPA-treated  rats  showed 
increased  GFAP  immunoreactivity  in  both  the 
CA1/CA2    as  well  as  the  CA3/Dentate  gyrus  (DG) 
regions  of  the  hippocampus  compared  to  controls  (t 
(10)  =  2.72.,  p<0.05;  t  (10)  =  3.26.,  p<0.01, 
respectively). PPA treated rats also showed increased 
levels  of  GFAP  immunoreactivity  in  white  matter 
however no significant group differences were revealed 
(Fig. 3). 
 
CD68:  Analyses  revealed  PPA-related  increases  in 
CD68 immunoreactivity in the CA1/CA2 region of the 
hippocampus  (t  (10)  =  2.93,  p<0.05)  and  in  white 
matter(t  (10)  =  3.23,  p<0.01).  PPA-treated  tissue 
showed  an  increased  CD68  immunoreactivity  in  the 
CA3/DG  region  however  the  difference  failed  to  be 
significant (t (10) = 2.22, p = 0.051) (Fig. 3) 
Iba1: Qualitative assessments of Iba1 staining revealed 
increased cytoplasmic processes in PPA treated brains 
indicative  of  activated  microglia,  however,  no 
significant group differences were obtained (Fig. 3).  
 
Caspase 3’ and NeuN: PPA treatment did not cause 
increased amounts of activated cell death (caspase 3’) 
in either the CA1/CA2 (t (10) = 0.068, p = 0.95) or 
CA3/DG  (t  (10)  =  0.35,  p  =  0.74)  regions  of  the 
hippocampus or in white matter (t (10) = 0.83, p = 0.42) 
compared to controls. Analyses also revealed that PPA 
treatment  did  not  cause  pyramidal  cell  loss  (NeuN 
immunoreactivity)     in     either       the        CA1/CA2 
(t (10) = 0.30, p = 0.77)   or     CA3/DG (t (10) = 0.26, 
p  =  0.80)  regions  of  the  hippocampus  compared  to 
controls. Taken together, these results suggest that PPA 
is not directly cytotoxic at doses capable of producing 
behavioral effects in this experiment (Fig. 3).  Am. J. Biochem. & Biotech., 4 (2): 146-166, 2008 
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Fig. 3:  Representative  photomicrographs  (avidin-biotin/diaminobenzidine  immunohistochemistry,  haematoxylin 
counterstain)  of  dorsal  hippocampus  (CA2  region)  and  adjacent  external  capsule  white  matter  of  rats 
receiving  ipsilateral  intraventricular  infusions  of  PBS  or  PPA  twice  daily  for  7  days.    PPA  produces 
significant increases in reactive astrogliosis (GFAP immunoreactivity) and macrophage derived activated 
microglia (CD68 immunoreactivity). These findings are coupled  with an absence of apoptosis (cleaved 
Caspase 3’) or hippocampal pyramidal cell loss (NeuN immunopositive cell counts). p*<0.05, **p<0.01, 
bars represent mean values (±SEM) for PBS and PPA treated groups (original magnification 25x, scale bar 
represents 100 µm). Arrows indicate immunopositive cells 
 
Qualitative assessments: In PPA treated rats the above 
neuroinflammatory  markers  (GFAP,  CD68  and  Iba1) 
were most intense near the site of the infusion cannula, 
periventricular  regions  hippocampus,  neocortex 
(frontal,  parietal  and  cingular  cortices)  and  external 
capsule. Reactions were more intense ipsilateral to the 
infusion  cannula.  We  could  not  qualitatively  observe 
any  changes  in  midbrain,  cerebellum  and  brain  stem 
from PPA treated rats. PBS control rats showed minor 
neuroinflammatory changes adjacent to the cannula site 
(Fig. 4A-H).  
 
Regional effects of PPA on oxidative stress makers 
and GSH metabolism 
Lipid  peroxidation:  Following  PPA  treatment,  the 
concentration  of  lipid  peroxidation markers MDA andAm. J. Biochem. & Biotech., 4 (2): 146-166, 2008 
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Fig. 4: Neuropathological  effects  of  repeated  intraventricular  infusions  (twice  daily´7  days)  of  PPA  in  rat 
hippocampal formation (avidin-biotin/diaminobenzidine immunohistochemistry, haematoxylin counterstain): 
Coronal sections at the level of ispilateral dorsal hippocampus of PBS control (A,C,E,G) or PPA (B,D,F,H) 
infused  rodents  from  behavioral  study  eliciting  increased  locomotor  activity.  PPA  produced  a  diffuse 
increase of GFAP immunoreactivity (arrows) in hippocampal formation, internal capsule, neo- and cingulate 
cortex, and periventricular regions (B) greater than PBS controls (A). High power magnification at level of 
pyramidal cell layer and stratum oriens (CA-2) of  same  animals showed hypertrophy of GFAP labeled 
astrocytes suggestive of reactive astrogliosis in PPA treated rats (D) compared to controls (C). PPA also 
produced a qualitative increase in Iba1 immunoreactivity (arrow) in similar regions of PPA treated brain (F) 
compared to control (E). High power magnification of similar region in CA-2 shows an increase in Iba1 
labeled activated microglial processes with PPA treatment (H), compared to resting microglia in PBS treated 
brain (G)  (original magnifications 1.6x and 63x, scale bar represents 1mm and scale bar represents 50µm, 
respectively) Am. J. Biochem. & Biotech., 4 (2): 146-166, 2008 
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Fig. 5: Group mean (±SEM) for (A) Malondialdehye (MDA) and 4-hydroxy-2,3-nonenal  (4-HNE), (B) protein 
carbonyls, (C) superoxide dismutase (SOD) and (D) catalase. PPA induces a significant increase in lipid and 
protein oxidation and a decrease in catalase activity, supportive of increased oxidative stress via increased 
oxidant production, and decreased antioxidant defenses p*<0.05, **p<0.01 
 
HNE  increased  significantly  in  the  cortex,  thalamus, 
striatum  (t  (16)  =  2.47,  2.18  and  2.89,  respectively, 
p<0.05  for  each  region)  but  not  in  hippocampus, 
cerebellum and brain stem compared to PBS controls 
(Fig. 5A).  
 
Protein  oxidation:  PPA  treatment  significantly 
increased the concentration of protein carbonyls in all 
brain areas studied (t (16) = 3.04, 2.71, 2.89 and 3.46, 
for  cortex,  hippocampus,  thalamus  and  striatum 
respectively),  except  for  cerebellum  and  brain  stem 
(p<0.05 or better for each region) (Fig. 5B).  
 
SOD  and  Catalase:  Total  SOD  enzymatic  activity, 
which specifically dismutates superoxide radical, also 
did not show inter area differences between groups for 
any of the brain regions studied (Fig. 5C).  
  Catalase  activity  was  successfully  measured  in  3 
PBS  and  8  PPA  treated  animals.  Catalase  activity 
decreased in the hippocampus, striatum and cerebellum 
(t  (9)  =  2.30,  4.10  and  2.61,  respectively  p<0.05  or 
better for each region) in PPA treated rats (Fig. 5D).  
 
Total  GSH  and  GPx:  PPA  treated  animals  showed 
decreased total GSH in cortex (t (16) = 2.39, p<0.05) 
compared  to  controls  (Fig.  6A).  No  significant 
differences  were  found  between  treatment  groups  for 
GPx (Fig. 6B). 
 
GR and GST: GR activity was relatively stable among 
areas independent of treatment (Fig. 6C). The activity 
of  GST  increased  in  all  brain  areas  except  for 
hippocampus (t (16) = 3.36, 4.24, 3.21, 3.87, 3.48 for 
cortex, thalamus, striatum, cerebellum and brain stem, 
respectively, p<0.01 for each region) (Fig. 6D). 
  The  results  from the present study indicated that 
repeated intraventricular infusions of PPA in adult rats 
produces increased amounts of locomotor activity and 
increased  immunoreactivity  of  innate 
neuroinflammatory markers. Repeated PPA treatments 
also  caused  increased  protein  carbonylation  and 
lipoperoxidation  suggestive  of  increased  oxidative 
stress.  PPA  caused  a  decrease  in  catalase  activity 
suggesting an impairment in antioxidant defenses. PPA 
also reduced total glutathione and impaired glutathione 
metabolism in discrete brain regions.  
 
Behavior: PPA treated rats exhibited a greater number 
of  movements  and  movement  time  compared  to 
controls   on  the  first  6 of the 7 infusion days. Vertical Am. J. Biochem. & Biotech., 4 (2): 146-166, 2008 
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Fig. 6:  Group  means  (±SEM)  for  (A)  glutathione  (GSH),  (B)  glutathione  peroxidase  (GPx),  (C)  glutathione 
reductase (GR), (D) glutathione s-transferase (GST). PPA treated rats showed significantly decreased total 
GSH in cortex and increase in the activity of GST. The activity of GPx and GR were unaffected. These 
findings suggest that GSH may be involved in the metabolic clearance of PPA, or alternatively, the synthesis 
of GSH was impaired by PPA. These data may reflex an overall reduction in antioxidant defenses induced 
by PPA. p*<0.05, **p<0.01 
 
activity was also elevated in PPA animals but was only 
significant  on  D6  compared  to  controls.  No  group 
differences  in  activity  were  found  on  D7.  These 
findings indicate that animals spent more time moving 
in the horizontal position which extends our previous 
observations  from  this  group  of  animals
[61].  In  our 
previous  study,  PPA  treated  rats  showed  increased 
amounts of total distance traveled between D1 and D6. 
Our present findings show that PPA infusions cause rats 
to  produce  more  movements  which  are  of  greater 
duration compared to controls. These findings are also 
consistent with our previous visual observations which 
revealed that PPA treated rats showed increased turning 
behaviors,  snake-like  postures,  limb  dystonia  and 
retropulsion. Furthermore, we also observed that PPA 
induced complex partial seizures and caudate spiking as 
measured by EEG recordings
[61].  
  PPA  possesses  many  neuropharmacological 
properties  which  can  account  for  the  short-latency 
behavioral effects observed in this study. PPA inhibits 
Na
+/K
+  ATPase
[78]  and  increases  NMDA  receptor 
sensitivity
[47] which can enhance neural depolarization. 
This organic acid increases glutamatergic transmission 
leading  to  neural  hyperexcitability  in  brain  regions 
linked  to  locomotor  activity.  PPA  also  promotes 
intracellular calcium release which is known to play a 
key  role  in  synaptic  transmission
[79,80]  and  elevates 
nitric  oxide
[60]  which  is  involved  in  cortical, 
hippocampal and striatal neurotransmission
[81-85].  
  An important effect of PPA is its ability to induce 
intracellular  acidification.  Our  previous  study  found 
that  only  PPA  and  not  1-propanol,  the  non-acidic 
analogue of PPA,  was capable of eliciting behavioral 
and electrophysiological effects. These findings suggest 
that  some  pH  or  monocarboxylate  dependent 
mechanism may account for the effects observed. PPA 
is a weak organic acid existing in equilibrium in both 
lipid and water soluble states. The lipid phase solubility 
enables  PPA  to  cross  the  lipid  bilayer  of  cells  and 
permits PPA to enter and equilibrate in neuronal and 
glial  cells.  Previous  studies  have  shown  that  cellular 
concentration of PPA produces a reversible intracellular Am. J. Biochem. & Biotech., 4 (2): 146-166, 2008 
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acidosis  and  this  effect  is  potentiated  by  minor 
reductions in extracellular pH
[52,86-89].  
  In addition to passive accumulation in CNS cells, 
there is also evidence that PPA and other short chain 
fatty  acids  are  specifically  taken  up  by 
monocarboxylate  receptors  in  cerebrovascular 
endothelium, neurons and glia
[90-92]. PPA is metabolized 
by  glial  cells  which  involves  the  propionyl  CoA 
carboxlyase enzyme
[93]. PPA increases the levels of the 
cytotoxin  propionyl  CoA  and  depletes  cytosolic 
carnitine  stores  leading  to  a  reduction  in  fatty  acid 
metabolism  by  mitochondria  which  can  cause  further 
reductions in intracellular pH
[50,51].   
  Intracellular  neuronal  acidification  produces 
widespread  effects  on  neurotransmitter  release 
including  glutamate,  dopamine,  norepinepherine  and 
serotonin, each of which can influence the production 
of  locomotor  activity
[94-98].  Furthermore,  alkylating 
analogues  of  PPA  including  3’3’-iminodipropionitrile 
and 3-nitroprioprionic acid have been used to produce 
rodent  models  for  movement  disorders  such  as 
Huntington’s  disease
[99,100].  Therefore  intracellular  pH 
reduction by PPA provides a possible explanation for 
the  PPA-induced  increases  in  locomotor  activity 
observed in the present study.  
  One interesting pH dependent effect of PPA is its 
ability  to  rapidly  and  reversibly  reduce  intercellular 
coupling  by  the  closure  of  gap  junctions
[52,101].  Gap 
junctions  are  composed  of  a  family  of  membrane 
proteins  known  as  the  connexins.  They  are  know  to 
play an important role in electrotonic neurotransmission 
in the basal ganglia, deep cerebellar nuclei, prefrontal 
cortex,  nucleus  accumbens  and  the  hippocampal 
formation  which  are  involved  in  the  production  of 
locomotor  activity
[102,103].    Closure  of  neural  gap 
junctions creates functional groups of neuronal clusters 
while  closure  of  glial  gap  junctions  causes  neural 
hyperexcitability  from  elevations  of  extracellular 
potassium.  This  is  thought  to  occur  through  the 
development of discrete gap junction linked clusters of 
neurons
[88,104].  Furthermore  closure  of  glial  gap 
junctions  by  PPA  could  lead  to  neuronal 
hyperexcitablilty by impaired glial spatial buffering of 
cytosolic  potassium  or  glutamate
[105].  Moreover, 
intrastriatal infusions of gap junction blockers produce 
movement  disorder  in  rodents
[106].  Thus,  the  altered 
neural  excitablility  of  neocortical,  hippocampal  and 
striatal neuronal groups in PPA treated rats would be 
consistent  with  the  closure  of  neural  or  glial  gap 
junctions by PPA
[101]. 
  PPA infusions did not induce significant increases 
in locomotor activity on D7 suggesting that the animals 
either  became  tolerant  to  PPA  treatment  or  a 
compensatory  mechanism  was  engaged.  Pathways 
underlying  a  compensatory  mechanism  include 
increased synthesis of PPA metabolizing enzymes such 
as propionyl CoA decarboxylase, induction of carbonic 
anhydrase  in  response  to  acidosis
[107]  or  induction  of 
pro-  inflammatory  (IL1-￿  and  TNF-￿)  or  anti-
inflammatory cytokines such as TGF-￿ or interferon-b 
by the observed proliferation of microglia
[108].  
  In  summary,  the  observation  of  increased 
locomotor activity in PPA-treated is consistent with the 
expectations  of  an  animal  model  for  autism.  These 
findings resemble the idiosyncratic bouts of repetitive 
behaviors  noted  in  autism.  Autism  has  been  grouped 
with the movement disorders
[109] and the contribution of 
seizures to these behaviors may be underappreciated
[3].  
 
Neuropathology:  PPA  treated  rats  showed  increased 
amounts of GFAP and CD68 immunoreactivity in the 
hippocampus  and  as  well  as  a  significant  increase  in 
CD68  in  white  matter.  The  most  significant  findings 
occurred in the CA1/CA2 region of the hippocampus 
for  each  marker.  Qualitatively,  this  pathological 
response was concentrated around the cerebrovascular 
endothelium.  These  findings  collectively  suggest  an 
innate  neuroinflammatory  response  characterized  by 
reactive  astrogliosis  and  activated  microglia.  These 
findings are similar to, but not as robust as, the GFAP 
and CD68 immunoreactivity seen in rats treated with 
PPA for 13 consecutive days
[61]. Reactive astrogliosis is 
a  common  indicator  for  direct  neurotoxic
[110]  and 
neuroplastic  effects
[111].  The  more  pronounced 
immunoreactivity of CD68, a marker of microglia and 
macrophages
[112]  coupled  with  the  lack  of  significant 
Iba1 staining may suggest a PPA-induced recruitment 
of  peripheral  macrophages  to  the  CNS.  This  is 
conceivable  as  short  chain  fatty  acid  receptors  are 
known to exist on immune cells and have chemotactic 
and proliferative effects
[53].  
  Interestingly, neither group showed gross neuronal 
loss  in  either  the  hippocampus  or  white  matter  as 
evidenced  by  the  lack  of  group  differences  in  either 
caspase  3’  or  NeuN  immunoreactivity  (direct  cell 
counts and total area stained).  This suggests that PPA 
is  not  grossly  cytotoxic,  at  least  in  the  brain  areas 
directly studied. This finding is in direct contrast to a 
number  of  other  neuropathological  conditions  that 
produce neuroinflammation coupled with neuronal loss 
such  as  Parkinson
[113]  and  Alzheimer  disease
[114], 
epilepsy
[68],  and AIDS dementia complex
[115].  These 
observations  have been  substantiated by a  number of 
complementary  rodent  models  such  as  kainic  acid 
induced  seizures
[116],  experimental  autoimmune Am. J. Biochem. & Biotech., 4 (2): 146-166, 2008 
 
  158 
encephalomyelitis
[117]  and  bacterial  lipopoly-
saccharide
[113,118]. 
  The above neuropathological findings in the PPA 
rat model are similar to findings from brain tissue of 
autistic patients. Similarities include activated microglia 
and reactive astrocytes in hippocampus and neocortex, 
changes  in  white  matter,  coupled  with  comparatively 
minor effects in  neuronal cytoarchitecture
[6].  Reactive 
astrocytes  and  activated  microglia  release  cytokines 
including  tumor  necrosis  factor  and  macrophage 
chemoattractant  protein,  which  contribute  to  the 
neuroinflammatory  response  and  are  elevated  in 
autism
[66].  Microglia  produce  inducible  nitric  oxide 
synthetase,  leading  to  the  production  of  nitric  oxide, 
reactive oxygen species (ROS) and increased oxidative 
stress
[119].  This neuroinflammatory process is localized 
near  the  cerebral  endovasculature  suggesting  that 
altered  permeability  of  the  blood  brain  barrier  and 
impaired  cerebral  blood  flow  may  be  components  of 
autism
[120;121]. Furthermore, specific G-protein coupled 
receptors  (e.g.,  GPR41  and  GPR43)  for  short  chain 
fatty acids have been identified on a number of immune 
cells including neutrophils
[122] suggesting that PPA may 
be involved in the activation of the immune response.  
  It  is  unclear  whether  this  neuroinflammatory 
response  is  responsible  for,  or  restorative  to  the 
behavioral  and  pathophysiological  effects  of  autism. 
One  could  propose  the  latter,  since  the  PPA  induced 
behavioral effects occurred within minutes of infusion, 
while  activation  of  astrocytes  and  microglia,  require 
hours  to  occur
[123].    Further  studies  to  examine  the 
temporal  distribution  of  these  and  other  relevant 
neuroinflammatory markers will need to be performed. 
 
Biochemistry:  PPA  infusions  caused  an  increase  in 
oxidative  stress  markers,  a  decrease  in  antioxidant 
production  and  an  impairment  in  glutathione 
metabolism in most brain regions. Interestingly, these 
biochemical effects were more widespread in the CNS 
and occurred in areas distal from the infusion site (e.g. 
cerebellum) compared to pathological findings. These 
observations are similar to the findings reported in our 
recent  paper
[61]  which  analyzed  homogenates  from 
whole brain and another recent report that examined the 
effects  of  direct  intrastriatal  infusion  of  PPA  in 
rodents
[124].   
  Malondialdehyde  (MDA)  and  4-hydroxy-2,  3-
nonenal  (4-HNE)  are  both  used  as  key  indicators  of 
lipid  peroxidation,  while    many  of  the  reactions 
mediated  by  ROS  conclude  in  the  introduction  of 
carbonyl groups into proteins
[73].  Although increased 
trends  existed  in  all  brain  regions,  PPA  infusions 
produced  significantly  increased  amounts  of 
MDA/HNA  and  protein  carbonyls  in  the  cortex, 
thalamus and striatum and increased carbonylation in 
hippocampus.  These  findings  suggest  that  ICV 
infusions  of  PPA  produce  widespread  induction  of 
lipoperoxidation and protein carbonylation, presumably 
by the production of ROS.  
  The activity of the antioxidant enzyme SOD was 
not altered by PPA treatment. However, the activity of 
the antioxidant enzyme catalase was decreased by PPA 
in  many  brain  regions  with  significant  group 
differences occurring in the hippocampus, striatum and 
cerebellum. These findings are similar to studies which 
found  a  reduction  in  catalase  activity  in  erythrocytes 
from autistic patients
[28]. 
  Increased  oxidative  damage,  putatively  via 
neuroinflammation,  mitochondrial  dysfunction, 
carnitine reduction and impaired GSH metabolism, may 
be  an  important  aspect  of  autism
[29,30,125]. 
Lipoperoxidation  of  CNS  membranes  are  thought  to 
lead to alterations in membrane lipid composition and 
fluidity,  which  has  been  proposed  as  playing  a 
causative  role  in  the  disorder
[27].  Furthermore, 
biochemical  processes  common  to  those  observed  in 
oxidative stress have been proposed as mechanisms of 
synaptic plasticity
[126]. 
  PPA treated animals showed decreased total GSH 
in  cerebral  cortex.  GPx  and  GR  activity  were 
unchanged.  PPA  treatment  produced  increased  GST 
levels  in  PPA  treated  animals  compared  to  controls 
suggesting  that  perhaps  GSH  was  being  used  for  the 
removal of PPA or related catabolites or, alternatively, 
that  the  production  of  GSH  was  impaired.  These 
findings are interesting since GSH plays a major role in 
cellular antioxidant defense, methylation pathways and 
in the integrity of the blood brain barrier
[32]. GSH also 
is a major detoxifier of a broad range of xenobiotics and 
certain metals, some of which have been suggested to 
be  relevant  as  risk  factors  for  autism
[30,33].  Genetic 
variations  in  GSH  metabolism  may  exist  in  some 
populations  at  increased  risk  for  autism
[31]. 
Interestingly, oxidation of glutathione has been shown 
to result in the closure of gap junctions and thus may be 
a  mechanism  for  reduction  of  connexin-dependent 
intercellular  communication  during  acidosis  or 
increased oxidative stress
[127]. Reductions in brain GSH 
have been found in other pathological conditions such 
as  experimental  methylmalonic  acidemia
[128],  2-
chloropropionic  acid  administration
[129],  experimental 
hyperphenylalaninemia
[130]  and  picrotoxin  induced 
seizures
[131].  
  Possible mechanisms mediating the GSH decrease 
in neocortex include increased oxidation, release from 
the  mitochondria  and/or  decreased  import  from  the Am. J. Biochem. & Biotech., 4 (2): 146-166, 2008 
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cytosol.  Since  our  analysis  system  recycles  GSSG  to 
GSH,  decreases  observed  are  due  to  loss  of  GSH, 
possibly  by  conjugation  in  xenobiotics  metabolism. 
Furthermore, GST was also  increased suggesting that 
the decreased concentration  of total GSH induced by 
PPA  is  likely  due  to  GSH  consumption  by  its 
conjugation  with  xenobiotics.  This  decline  in  GSH 
could render cells more susceptible to oxidative stress, 
which might account for the increased protein and lipid 
oxidation detected in the brain of PPA treated rats
[132]. 
However,  the  decreased  concentration  of  total  GSH 
may also be related to a reduction in ATP- dependent 
synthesis. The reductions in GSH could be due to the 
impaired synthesis of GSH by PPA. However, because 
this decline was associated with increased GST activity 
these  results  are  more  suggestive  of  GSH  being 
involved in the metabolic clearance of PPA or related 
metabolites in most brain areas.  
  Whether  the  observed  reductions  in  GSH 
metabolism  in our study  were the result of a general 
impairment  in  GSH  synthesis  or  due  to  possible 
sequestration of GSH by PPA or related metabolites is 
unclear. Whether increased oxidative stress observed in 
our  study  leads  to  mitochondrial  failure,  or 
alternatively,  mitochondrial  failure  induced  by  PPA 
leads to oxidative stress is a subject of further study. 
Nonetheless,  the  observed  decline  in  GSH 
concentration may render CNS cells more susceptible 
to  oxidative  stress
[33],  which  could  account  for  the 
increased  protein  and  lipid  oxidation  detected  in  the 
brain of PPA treated rats and possibly human autism. 
  It  is  interesting  to  note  that  the  oxidative  stress 
effect of PPA administration was far more widespread 
in the brain than the innate neuroinflammatory effects, 
which  were  primarily  located  in  ipsilateral 
hippocampus,  neocortex  and  external  capsule  white 
matter. Other studies have also implicated subcortical 
areas  such  as  basal  ganglia
[133]  and  thalamus
[134]  in 
autism.  As well, behavioral effects of PPA occurred 
shortly after the first infusion suggesting that at least 
some  of  the  behavioral  effects  of  PPA  may  be 
independent of astro- and microglial activation. Indeed, 
astrogliosis may be protective and play a key role in 
repair  in  the  CNS  following  injury
[111].    As  we  used 
gross dissection regions for these initial oxidative stress 
studies, we cannot rule out PPA induced biochemical 
and  neuropathological  changes  in  discrete  cell 
populations (i.e., brain stem). 
 
SUMMARY 
 
  These  behavioral,  neuropathological  and 
biochemical findings in our rodent PPA model provide 
further support for the hypothesis that autism may be a 
systemic  metabolic  encephalopathic  process  affecting 
widespread  brain  regions  rather  than  a  static  primary 
brain  disorder  involving  discrete  CNS  areas
[21].  This 
work, coupled with our initial study
[61], shows that PPA 
can  produce  behavioral  changes  that  resemble  those 
found in ASD. Recently we have also found evidence 
of reversible impairments in social behavior following 
PPA exposure
[135].   
  The  similarities  in  innate  neuroinflammatory  and 
oxidative stress changes between the animal model and 
human ASD cases could represent similar metabolic or 
immune  mediated  processes
[9]  directly  or  indirectly 
associated  with  PPA.  Of  particular  interest  are  our 
observations  of  broad  impairments  in  the  GSH  and 
catalase  metabolism  which  could  provide  a  common 
mechanism for increased oxidative stress and increased 
environmental sensitivity to a variety of environmental 
compounds
[27]. 
  Despite  the  promise  of  the  PPA  rodent  model 
fulfilling some of the behavioral, neuropathological and 
biochemical criteria for autism
[136], some caution needs 
to be used in suggesting PPA as a possible risk factor 
for the human condition. Firstly, it should be noted that 
there  are  no  studies  directly  measuring  PPA  in  ASD 
patients.  However,  there  is  indirect  evidence  linking 
PPA  to  alterations  in  fatty  acid  metabolism
[137], 
deficiencies in carnitine
[125] and alterations in biotin
[138] 
in  autism.  There  are  similar  metabolic  trends  noted 
following  exposure  to  valproate,  a  teratogenic  risk 
factor  in  autism
[57].  Furthermore  PPA  producing  gut 
clostridial  species  have  been  found  in  a  subset  of 
patients with regressive ASD 
[40]. 
  Secondly,  our  initial  studies  have  used  mature 
rodents.  Given  the  known  effects  of  PPA  on 
neurodevelopmental  processes
[65]  (i.e.,  cell 
signalling
[139], gene expression
[140,141], apoptosis
[142] and 
modulation of gap junctions
[52]) future studies need to 
examine  the  effects  of  PPA  at  pre-  and  peri-natal 
developmental  stages.  However,  intraventricular 
administration  of  PPA  does  show  promise  as  an 
environmental trigger that links the disparate genetic, 
neuropathological  and  systemic  findings
[31]  associated 
with ASD.  
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